project id: TCGA-BLCA; case submitter id: TCGA-DK-A3IS; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.77; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.8; rna integrity number: 8.8; age at index: 68; days to birth: -25098; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1940; age at diagnosis: 25098; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc pathologic t: T2a; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1529.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: Not Reported; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2008; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; weight: 30.0; composition: Not Reported; days to collection: 1279; days to sample procurement: 0; initial weight: 100.0; portion submitter id: TCGA-DK-A3IS-01A-21; percent lymphocyte infiltration: 10.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 10.0; percent stromal cells: 0.0; percent tumor cells: 90.0; percent tumor nuclei: 90.0;